Eton Pharmaceutcials
ETON
12 hedge funds and large institutions have $12M invested in Eton Pharmaceutcials in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
70% more capital invested
Capital invested by funds: $7.05M → $12M (+$4.96M)
1.97% more ownership
Funds ownership: 6.54% → 8.51% (+2%)
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.68M |
| 2 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$437K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$187K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$80.2K |
| 5 |
Barclays
London,
United Kingdom
|
+$61.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
-$73K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$7K |
| 3 |
BlackRock
New York
|
-$4.38K |
| 4 |
Morgan Stanley
New York
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $6.12M | +$1.68M | +241,773 | +46% |
|
|
AIC
2
AWM Investment Company
New York
| $3.4M | – | – | – |
|
|
DC
3
Diametric Capital
Boston,
Massachusetts
| $975K | +$437K | +62,871 | +107% |
|
|
AMH
4
Apollo Management Holdings
New York
| $720K | – | – | – |
|
|
PCM
5
Prelude Capital Management
New York
| $295K | +$80.2K | +11,552 | +46% |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $216K | +$187K | +26,962 | New |
|
|
7
BlackRock
New York
| $75K | -$4.38K | -630 | -6% |
|
|
8
Barclays
London,
United Kingdom
| $70K | +$61.1K | +8,800 | New |
|
9
UBS Group
Zurich,
Switzerland
| $68K | +$59.3K | +8,542 | New |
|
10
Wells Fargo
San Francisco,
California
| $48K | – | – | – |
|
11
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $12K | +$9.18K | +1,321 | +440% |
|
|
TRCT
12
Tower Research Capital (TRC)
New York
| $11K | +$8.7K | +1,252 | +787% |
|
|
BFM
13
Boothbay Fund Management
New York
| – | -$73K | -11,966 | Closed |
|
|
14
Bank of America
Charlotte,
North Carolina
| – | -$7K | -1,118 | Closed |
|
|
15
Morgan Stanley
New York
| – | -$2K | -400 | Closed |
|
ETON Hedge Fund Activity: Q1 2019 in Review
12 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Eton Pharmaceutcials (ETON) for Q1 2019, worth a combined $12M — up 70% from $7.05M a quarter earlier.
Fund positioning in ETON was balanced in Q1 2019: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 1 trimmed.
The largest buyer was Opaleye Management, adding an estimated $1.68M. The largest seller was Boothbay Fund Management, exiting entirely with an estimated $73K sold.
- 12 institutional investors held Eton Pharmaceutcials (ETON) as of Q1 2019, unchanged from Q4 2018.
- Funds reported $12M of Eton Pharmaceutcials stock for Q1 2019, up 70% quarter-over-quarter.
- 3 funds opened new Eton Pharmaceutcials positions in Q1 2019 and 3 closed out, a net change of 0 holders.
- The largest Eton Pharmaceutcials buyer in Q1 2019 was Opaleye Management, an estimated $1.68M added.
- The largest Eton Pharmaceutcials seller in Q1 2019 was Boothbay Fund Management, an estimated $73K sold.
Based on aggregated 13F filings for Q1 2019.